Corbus Pharmaceuticals Holdings is a clinical stage pharmaceutical company focused on the development and commercialization of therapeutics to treat chronic and serious inflammatory and fibrotic diseases. The company's product, lenabasum, is a synthetic, oral, cannabinoid (CB2 agonist) designed to resolve chronic inflammation and halt fibrotic processes. The company is developing lenabasum to treat systemic sclerosis, dermatomyositis, cystic fibrosis and systemic lupus erythematosus. The company's pipeline also includes CRB-4001, a peripherally-restricted, CB1 inverse agonist designed to treat organ specific fibrotic liver diseases, such as nonalcoholic steatohepatitis.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.